Kester has completed the first and final close of Kester Capital Fund IV at its hard cap of £425 million, following a four-month fundraising period that attracted significant interest from both existing and new institutional backers. The close marks a substantial leap from the firm’s previous vehicle, which secured £200 million in third-party commitments.
The firm’s latest fund attracted blue-chip investors across the United States, Europe, and Asia, reflecting strong confidence in Kester’s thematic approach and long-term performance record. Fund IV will continue the firm’s strategy of investing in rapidly expanding companies within the Technology and Life Sciences sectors, where Kester aims to help management teams scale operations and establish category leadership.
The close of Fund IV follows an active deployment period for the London-based private equity firm. Over the past year, Kester has invested in Addresscloud, a provider of insurance risk intelligence; Re-flow, which delivers field service management software for critical infrastructure; and Evestia Clinical, a Clinical Research Organisation supporting global pharmaceutical and biotechnology customers.
Kester’s track record has played a central role in attracting a broad, diversified investor base, including pension funds, endowments, family offices, and asset managers. Since its inception, the firm has generated four exits exceeding four times the return and eight exceeding three times the return for its investors. Kester was also named PE House of the Year – Small-Cap at the 2024 Real Deals Private Equity Awards in recognition of sustained performance and sector specialization.
KEY QUOTES
“We are thrilled to announce the close of Fund IV at our hard cap of £425 million. To have secured such strong support is a testament to our investment strategy, the quality of our team and the excellent results we have delivered for our investors. We greatly value the trust and support of both our long-standing and new investors.”
Adam Maidment, Founder and Managing Partner
“Fund IV gives us the opportunity to continue to invest in our team and platform and to partner with the highest potential Technology and Life Sciences businesses. Our deep sector expertise and track record of driving value creation are more relevant than ever in today’s market.”
Cameron Crockett, Founder and Managing Partner
